TherapeuticsMD Inc (TXMD) USD0.001

Sell:$1.48Buy:$1.49No change

NASDAQ:0.38%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.48
Buy:$1.49
Change:No change
Market closed | Prices delayed by at least 15 minutes
Sell:$1.48
Buy:$1.49
Change:No change
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Key people

Thomas G. Thompson
Executive Chairman of the Board
Marlan D. Walker
Chief Executive Officer
Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Cooper C. Collins
Independent Director
Gail K. Naughton
Independent Director
Justin Roberts
Independent Director
Click to see more

Key facts

  • EPIC
    TXMD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US88338N2062
  • Market cap
    $17.13m
  • Employees
    1
  • Shares in issue
    11.57m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.